Guest guest Posted August 21, 2003 Report Share Posted August 21, 2003 Found this on the web. Hope it helps Mira http://patft.uspto.gov/netacgi/nph- Parser?Sect1=PTO2 & Sect2=HITOFF & p=1 & u=/netahtml/search- bool.html & r=7 & f=G & l=50 & co1=AND & d=ptxt & s1=4,888,346 & OS=4,888,346 & RS=4,888 ,346 Chronic herpes viral infections, including chronic genital herpes caused by the herpes simplex virus, Type 2, and chronic infections due to the Epstein-Barr virus, chronic fatigue syndrome, chronic inflammatory connective tissue disease, including rheumatoid arthritis and systemic lupus erythematous and related diseases, and multiple sclerosis are treated by the administration via a pharmacologically effective route of an essentially pure opiate receptor antagonist, preferably an essentially pure opiate receptor antagonist exhibiting a substantially higher blocking effectiveness against Mu opiate receptor sites than against Delta receptor sites, exemplified by naltrexone and naloxone, at a low doseconcentration, corresponding to about 1-10 mg per day for naltrexone, at which concentration Delta blocking activity is small, while Mu blocking activity is significant. ------------------------------------------------------------------------ Inventors: Bihari; Bernard (29 W. 15th St., New York, NY 10011); Drury; Finvola (25 Colby St., Rochester, NY 14610) Appl. No.: 433152 Filed: November 8, 1989 Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.